• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管生成:药物发现的一个组织原则?

Angiogenesis: an organizing principle for drug discovery?

作者信息

Folkman Judah

机构信息

Childrens Hospital and Harvard Medical School Boston, Massachusetts, USA.

出版信息

Nat Rev Drug Discov. 2007 Apr;6(4):273-86. doi: 10.1038/nrd2115.

DOI:10.1038/nrd2115
PMID:17396134
Abstract

Angiogenesis--the process of new blood-vessel growth--has an essential role in development, reproduction and repair. However, pathological angiogenesis occurs not only in tumour formation, but also in a range of non-neoplastic diseases that could be classed together as 'angiogenesis-dependent diseases'. By viewing the process of angiogenesis as an 'organizing principle' in biology, intriguing insights into the molecular mechanisms of seemingly unrelated phenomena might be gained. This has important consequences for the clinical use of angiogenesis inhibitors and for drug discovery, not only for optimizing the treatment of cancer, but possibly also for developing therapeutic approaches for various diseases that are otherwise unrelated to each other.

摘要

血管生成——新血管生长的过程——在发育、生殖和修复中起着至关重要的作用。然而,病理性血管生成不仅发生在肿瘤形成过程中,还发生在一系列可归类为“血管生成依赖性疾病”的非肿瘤性疾病中。通过将血管生成过程视为生物学中的“组织原则”,可能会对看似不相关现象的分子机制获得有趣的见解。这对血管生成抑制剂的临床应用和药物发现具有重要意义,不仅有助于优化癌症治疗,还可能为开发针对各种原本互不相关疾病的治疗方法提供帮助。

相似文献

1
Angiogenesis: an organizing principle for drug discovery?血管生成:药物发现的一个组织原则?
Nat Rev Drug Discov. 2007 Apr;6(4):273-86. doi: 10.1038/nrd2115.
2
[VEGF, anti-vEGF and diseases].[血管内皮生长因子、抗血管内皮生长因子与疾病]
Bull Acad Natl Med. 2008 Feb;192(2):289-300; discussion 300-2.
3
Angiogenesis inhibitors in cancer therapy.癌症治疗中的血管生成抑制剂
Curr Opin Investig Drugs. 2003 Jun;4(6):667-74.
4
Diverse effects of statins on angiogenesis: new therapeutic avenues.他汀类药物对血管生成的不同影响:新的治疗途径。
Pharmacotherapy. 2010 Feb;30(2):169-76. doi: 10.1592/phco.30.2.169.
5
Angiotherapeutics from natural products: from bench to clinics?源于天然产物的血管治疗药物:从实验室到临床?
Clin Hemorheol Microcirc. 2003;29(3-4):199-203.
6
Different ways to antiangiogenesis by angiostatin and suramin, and quantitation of angiostatin-induced antiangiogenesis.血管抑素和苏拉明抗血管生成的不同方式以及血管抑素诱导抗血管生成的定量分析
APMIS. 2007 Jan;115(1):30-46. doi: 10.1111/j.1600-0463.2007.apm_405.x.
7
Is angiogenesis an organizing principle in biology and medicine?血管生成是生物学和医学中的一个组织原则吗?
J Pediatr Surg. 2007 Jan;42(1):1-11. doi: 10.1016/j.jpedsurg.2006.09.048.
8
Understanding the biology of angiogenesis: review of the most important molecular mechanisms.了解血管生成生物学:重要分子机制综述
Blood Cells Mol Dis. 2007 Sep-Oct;39(2):212-20. doi: 10.1016/j.bcmd.2007.04.001. Epub 2007 Jun 6.
9
Use of angiogenesis inhibitors in tumour treatment.血管生成抑制剂在肿瘤治疗中的应用。
Eur J Cancer. 2005 May;41(8):1109-16. doi: 10.1016/j.ejca.2005.02.017.
10
Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.血管生成:药物干预在癌症、心血管疾病和慢性炎症治疗中的潜力。
Pharmacol Rev. 2000 Jun;52(2):237-68.

引用本文的文献

1
Design and synthesis of 3,4--Lupane triterpene derivatives: targeting tumor angiogenesis and inducing apoptosis in triple-negative breast cancer.3,4-羽扇烷三萜衍生物的设计与合成:靶向肿瘤血管生成并诱导三阴性乳腺癌细胞凋亡
Front Chem. 2025 Jul 31;13:1630939. doi: 10.3389/fchem.2025.1630939. eCollection 2025.
2
Unleashing the anti-tumor angiogenic potential of nano-formulated orientin: In Silico, In Vitro, and In Ovo studies.释放纳米制剂荭草素的抗肿瘤血管生成潜力:计算机模拟、体外和鸡胚内研究
PLoS One. 2025 Jul 18;20(7):e0322564. doi: 10.1371/journal.pone.0322564. eCollection 2025.
3
Molecular Mediated Angiogenesis and Vasculogenesis Networks.
分子介导的血管生成和血管发生网络
Int J Mol Sci. 2025 Jun 30;26(13):6316. doi: 10.3390/ijms26136316.
4
A dynamic scapping workflow for RTK domains: computational modeling of natural products as dual modulators of EGFR and VEGFR signaling in breast cancer.一种用于受体酪氨酸激酶(RTK)结构域的动态筛选工作流程:天然产物作为乳腺癌中表皮生长因子受体(EGFR)和血管内皮生长因子受体(VEGFR)信号传导双重调节剂的计算建模
Mol Divers. 2025 Jul 10. doi: 10.1007/s11030-025-11263-x.
5
The Role of Extracellular Vesicles in the Control of Vascular Checkpoints for Cancer Metastasis.细胞外囊泡在癌症转移血管检查点控制中的作用
Cancers (Basel). 2025 Jun 12;17(12):1966. doi: 10.3390/cancers17121966.
6
Viral oncogenesis in cancer: from mechanisms to therapeutics.癌症中的病毒致癌作用:从机制到治疗
Signal Transduct Target Ther. 2025 May 12;10(1):151. doi: 10.1038/s41392-025-02197-9.
7
Systemic heparin administration impairs lung development in neonatal mice.全身性给予肝素会损害新生小鼠的肺发育。
Sci Rep. 2025 May 1;15(1):15273. doi: 10.1038/s41598-025-99831-x.
8
Structure-activity relationship guided design, synthesis and biological evaluation of novel diaryl urea derivatives as antiproliferative agents.基于构效关系指导的新型二芳基脲衍生物作为抗增殖剂的设计、合成及生物学评价
BMC Chem. 2025 Apr 22;19(1):107. doi: 10.1186/s13065-025-01478-2.
9
Blocking Tumoral Angiogenesis VEGF/VEGFR Pathway: Bevacizumab-20 Years of Therapeutic Success and Controversy.阻断肿瘤血管生成VEGF/VEGFR通路:贝伐单抗——20年的治疗成功与争议
Cancers (Basel). 2025 Mar 27;17(7):1126. doi: 10.3390/cancers17071126.
10
Integrating cuproptosis and immunosenescence: A novel therapeutic strategy in cancer treatment.整合铜死亡与免疫衰老:癌症治疗中的一种新治疗策略。
Biochem Biophys Rep. 2025 Mar 27;42:101983. doi: 10.1016/j.bbrep.2025.101983. eCollection 2025 Jun.